Arbutus Biopharma (NASDAQ: ABUS) reported Q2 EPS of ($0.03), in-line with the analyst estimate of ($0.03). Revenue for the quarter came in at $10 thousand versus the consensus estimate of $450 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.